As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.
Pfizer/Merck KGaA scrap a pivotal trial, partly because it tested Bavencio against what is no longer the relevant standard of care.
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Fears about flattening Opdivo sales were surely a major driver for Bristol's move for Celgene. To keep growing the checkpoint inhibitor needs some big clinical wins.
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Until now all PD-(L)1 blockers were assumed to have broadly similar activity, with any differences being put down to trial design; the latest renal cancer data could…